Search Results - "Morris, Don G."

Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer by Abbott, Annalise G, Meyers, Daniel E, Elmi-Assadzadeh, Golpira, Stukalin, Igor, Marro, Alessandro, Puloski, Shannon K T, Morris, Don G, Cheung, Winson Y, Monument, Michael J

“…Bone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond…”
Get full text

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer by Mostafa, Ahmed A, Meyers, Daniel E, Thirukkumaran, Chandini M, Liu, Peter J, Gratton, Kathy, Spurrell, Jason, Shi, Qiao, Thakur, Satbir, Morris, Don G

“…As the current efficacy of oncolytic viruses (OVs) as monotherapy is limited, exploration of OVs as part of a broader immunotherapeutic treatment strategy for…”
Get full text

Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma by THIRUKKUMARAN, Chandini M, ZHONG QIAO SHI, MORRIS, Don G, LUIDER, Joanne, KOPCIUK, Karen, HE GAO, BAHLIS, Nizar, NERI, Paola, PHO, Mark, STEWART, Douglas, MANSOOR, Adnan

“…Despite the recent advances made in the treatment of multiple myeloma, the disease still remains incurable. The oncolytic potential of reovirus has previously…”
Get full text

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database by Grosjean, Heidi A I, Dolter, Samantha, Meyers, Daniel E, Ding, Philip Q, Stukalin, Igor, Goutam, Siddhartha, Kong, Shiying, Chu, Quincy, Heng, Daniel Y C, Bebb, D Gwyn, Morris, Don G, Cheung, Winson Y, Pabani, Aliyah

“…The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the…”
Get full text

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy by Meyers, Daniel E, Wang, Amanda A, Thirukkumaran, Chandini M, Morris, Don G

“…Oncolytic viruses (OV) represent a promising strategy to augment the spectrum of cancer therapeutics. For efficacy, they rely on two general mechanisms:…”
Get full text

Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic by THIRUKKUMARAN, Chandini M, NODWELL, Michael J, NISHIKAWA, Sandra, DONNELLY, Bryan, COFFEY, Matt, TRPKOV, Kiril, FONSECA, Kevin, SPURRELL, Jason, MORRIS, Don G, HIRASAWA, Kensuke, SHI, Zhong-Qiao, DIAZ, Roman, LUIDER, Joanne, JOHNSTON, Randal N, FORSYTH, Peter A, MAGLIOCCO, Anthony M, LEE, Patrick

“…Reovirus is a nonattenuated double-stranded RNA virus that exploits aberrant signaling pathways allowing selective cytotoxicity against multiple cancer…”
Get full text

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma by Meyers, Daniel E., Thakur, Satbir, Thirukkumaran, Chandini M., Morris, Don G.

“…Multiple Myeloma (MM), a clonal malignancy of antibody-producing plasma cells, is the second most common hematologic malignancy and results in significant…”
Get full text

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors by Meyers, Daniel E., Pasternak, Meghann, Dolter, Samantha, Grosjean, Heidi A.I., Lim, Chloe A., Stukalin, Igor, Goutam, Siddhartha, Navani, Vishal, Heng, Daniel Y.C., Cheung, Winson Y., Morris, Don G., Pabani, Aliyah

“…Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of…”
Get full text

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors by Sander, Michael S., Stukalin, Igor, Vallerand, Isabelle A., Goutam, Siddhartha, Ewanchuk, Benjamin W., Meyers, Daniel E., Pabani, Aliyah, Morris, Don G., Heng, Daniel Y. C., Cheng, Tina

“…Background Metastatic uveal melanoma (MUM) is associated with poor survival and inferior response to immune checkpoint inhibitor (ICI) therapy when compared…”
Get full text

Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm? by Lawson, Keith A, Morris, Don G

“…Despite the development of novel targeted therapies, metastatic renal cell carcinoma (mRCC) remains an incurable disease. The known responsiveness of mRCC to…”
Get more information

Oncolytic Viral Therapy Using Reovirus by Thirukkumaran, Chandini, Morris, Don G

“…Current mainstays in cancer treatment such as chemotherapy, radiation therapy, hormonal manipulation, and even targeted therapies such as Trastuzumab…”
Get more information

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors by Meyers, Daniel E, Stukalin, Igor, Vallerand, Isabelle A, Lewinson, Ryan T, Suo, Aleksi, Dean, Michelle, North, Scott, Pabani, Aliyah, Cheng, Tina, Heng, Daniel Y C, Bebb, D Gwyn, Morris, Don G

“…Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of several solid tumor types. However, as patient outcomes are heterogeneous,…”
Get full text

Machine learning for prediction of cutaneous adverse events in patients receiving anti–PD-1 immunotherapy by Lewinson, Ryan T., Meyers, Daniel E., Vallerand, Isabelle A., Suo, Aleksi, Dean, Michelle L., Cheng, Tina, Bebb, D. Gwyn, Morris, Don G.

Get full text

Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future by Thirukkumaran, Chandini M., Morris, Don G.

“…Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide…”
Get full text

Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E Mutations by Burbidge, Toni E, Bastian, Boris C, Guo, Danny, Li, Haocheng, Morris, Don G, Monzon, Jose G, Leung, Gabriella, Yang, Huiming, Cheng, Tina

“…Abstract There is limited information on how indoor tanning promotes melanoma development. We investigated indoor tanning use in patients with melanomas in…”
Get full text

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors by Morris, Don G., Feng, Xiaolan, DiFrancesco, Lisa M., Fonseca, Kevin, Forsyth, Peter A, Paterson, Alexander H., Coffey, Matt C., Thompson, Brad

“…Summary Purpose This open-labeled, phase I clinical trial was designed to determine the safety and tolerability of percutaneous intralesional administration of…”
Get full text

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors by Cook, Sarah, Samuel, Vanessa, Meyers, Daniel E, Stukalin, Igor, Litt, Ishjot, Sangha, Randeep, Morris, Don G, Heng, Daniel Y C, Pabani, Aliyah, Dean, Michelle, Navani, Vishal

“…Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with…”
Get full text

A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin by Khanolkar, Rutvij A., Kalra, Amit, Kinzel, Megan, Pratt, Laura M., Dharmani-Khan, Poonam, Chaudhry, Ahsan, Williamson, Tyler S., Daly, Andrew, Morris, Don G., Khan, Faisal M., Storek, Jan

“…Intensified immunosuppressive prophylaxis for graft-versus-host disease (GVHD) may be toxic and therefore warranted only in patients at high risk of developing…”
Get full text

A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort by Kornaga, Elizabeth N, Klimowicz, Alexander C, Guggisberg, Natalia, Ogilvie, Travis, Morris, Don G, Webster, Marc, Magliocco, Anthony M

“…Breast cancers are routinely assessed for estrogen receptor status using immunohistochemical assays to assist in patient prognosis and clinical management…”
Get full text

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade by Navani, Vishal, Meyers, Daniel E., Ruan, Yibing, Boyne, Devon J., O'Sullivan, Dylan E., Dolter, Samantha, Grosjean, Heidi AI, Stukalin, Igor, Heng, Daniel Y.C., Morris, Don G., Brenner, Darren R., Sangha, Randeep, Cheung, Winson Y., Pabani, Aliyah

“…Immune checkpoint inhibitors (ICI) have revolutionized non-small cell lung cancer (NSCLC). We aimed to identify baseline characteristics, that are prognostic…”
Get full text